Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

COMMENTED

Osteoporosis

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

Osteoporos Int.

Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R

doi: 10.1007/s00198-018-4460-6.

Osteoporosis

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis

Clin Interv Aging.

Mederle OA, Balas M, Ioanoviciu SD, Gurban CV, Tudor A, Borza C

doi: 10.2147/CIA.S170111.

Osteoporosis

Trabecular bone microarchitecture predicts fragility fractures in postmenopausal women on denosumab treatment

Bone.

Butscheidt S, Rolvien T, Vettorazzi E, Frieling I

doi: 10.1016/j.bone.2018.06.022.

Osteoporosis

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Ann Intern Med.

Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians

doi: 10.7326/M15-1361.

Osteoporosis

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Lancet Diabetes Endocrinol.

McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.

doi: 10.1016/S2213-8587(19)30346-8.

COMMENTED

Osteoporosis

Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials

Climacteric.

Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J

doi: 10.1080/

Osteoporosis

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

Adv Ther

Kendler DL, Cosman F, Stad RK, Ferrari S

doi: 10.1007/s12325-021-01936-y

Melanoma and Skin Cancer

Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides

JAMA Dermatol.

Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Paul-Gunther S, Hofer A, Gruber-Wackernagel A, Legat F, Patra V, Quehenberger F, Cerroni L, Clark R, Wolf P

doi: 10.1001/jamadermatol.

Osteoporosis

Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years

J Clin Endocrinol Metab.

Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, Tierney A, Wagman RB, McClung M

doi: 10.1210/jc.2018-01965.

Related content

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis

Trabecular bone microarchitecture predicts fragility fractures in postmenopausal women on denosumab treatment

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides

Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years